|
|||||||||||||||||||||
|
|
Human PAI-1 ELISAPlasminogen activator inhibitor 1 (PAI-1) is a member of a family of proteins that inhibit plasminogen activators. It is a single-chain glycoprotein with a molecular weight of 47 kDa. PAI-1 is the primary inhibitor of tPA and other plasminogen activators in the blood. PAI-1 is mainly produced by the endothelial cells. PAI-1 is also synthesized by adipose tissue. The production of PAI-1 by adipose tissue that elevates plasma PAI-1 levels was observed in insulin resistant patients. Increased PAI-1 levels have been shown to be associated with a number of atherosclerotic risk factors. Insulin and proinsulin correlate with PAI-1 levels. Patients with insulin resistance syndrome and diabetes mellitus tend to have increased PAI-1 levels. Weight loss and treatment aimed at lowering triglyceride and/or cholesterol levels have also been shown to lower PAI-1 levels. A. Benefits:
B. Principle of the technology PAI-1 ELISA is based on the principle of a solid phase enzyme-linked immunosorbent assay. The assay utilizes a mouse anti-human PAI-1 antibody for immobilization on the microtiter wells and goat anti-human PAI-1 antibodies along with streptavidin conjugated to horseradish peroxidase (HRP) for detection. The test sample is allowed to react simultaneously with the two antibodies, resulting in the PAI-1 molecules being sandwiched between the solid phase and enzyme-linked antibodies. After incubation, the wells are washed to remove unbound-labeled antibodies. A HRP substrate, TMB, is added to result in the development of a blue color. The color development is then stopped with the addition of Stop Solution changing the color to yellow. The concentration of PAI-1 is directly proportional to the color intensity of the test sample. Absorbance is measured spectrophotometrically at 450 nm. Figure 1 Figure 2
Related information:
©2007-2008 Signosis, Inc.
|
||||||||||||||||||||
